You are here: Industry Insights > Zyesami

News List

NRx seeks breakthrough therapy designation for Covid-19 treatment Pharmaceutical-Technology
January 04, 2022
In a randomised trial, the therapy demonstrated a statistically significant two-fold increased odds of survival.
FDA declines to grant EUA for NRx’s Zyesami to treat Covid-19 patients Pharmaceutical-Technology
November 08, 2021
The US Food and Drug Administration (FDA) has declined to grant an emergency use authorization (EUA) for NRx Pharmaceuticals’ therapy, Zyesami (aviptadil), to treat critical Covid-19 patients who have respiratory failure.
NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil) prnewswire
September 28, 2021
NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI™.
NRx and MannKind to develop Zyesami inhaler for respiratory ailments pharmaceutical-technology
August 05, 2021
NRx Pharmaceuticals has entered an agreement with MannKind to create a dry powder formulation of its investigational drug, Zyesami (aviptadil), for the treatment of various respiratory ailments.
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI (Aviptadil-acetate) Trial in the Nation of Georgia firstwordpharma
July 07, 2021
NRx Pharmaceuticals (Nasdaq: NRXP) today announced it is initiating clinical training of Nation of Georgia (Georgia) ICU physicians, in the use of intravenous ZYESAMI™ (Aviptadil- acetate) for emergency use in patients suffering with Critical COVID-19.
NRx Pharmaceuticals’ Zyesami yields positive data in EAP for Covid-19 pharmaceutical-technology
June 17, 2021
NRx Pharmaceuticals has reported positive results from the expanded access protocol (EAP) of its Zyesami (Aviptadil) in critical Covid-19 patients admitted to the ICU with respiratory failure.
NRx Pharmaceuticals seeks FDA EUA for Covid-19 therapy Zyesami pharmaceutical-technology
June 03, 2021
NRx Pharmaceuticals has submitted an application to the US Food and Drug Administration (FDA) seeking Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for the treatment of critically ill Covid-19 patients with respiratory failure.
NeuroRx Announces ZYESAMI Trial Met Primary Endpoint americanpharmaceuticalreview
March 30, 2021
NeuroRx reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with ...
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure prnewswire
March 29, 2021
NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 ...
Zyesami™ shows promise in critical COVID-19 patients with respiratory failure europeanpharmaceuticalreview
February 26, 2021
Preliminary data indicate that Zyesami reduces the length of hospital stay in critical COVID-19 patients treated with High Flow Nasal Cannula (HFNC) therapy or mechanical ventilation.

Previous page 1 2 Next page